CRISPR gene-editing cholesterol therapy cuts LDL by half in first human trial, offering possible one-time treatment to lower high cholesterol
A first-in-human CRISPR-Cas9 infusion lowered LDL cholesterol by about 50% and triglycerides by about 55% in 15 adults with resistant lipid disorders, with effects lasting at least 60 days, according to a pilot report in the New England Journal of Medicine.
Key takeaways
- Study type: First-in-human, Phase 1 pilot trial in 15 adults with lipid disorders resistant to standard therapy.
- Effectiveness: ~50% reduction in LDL cholesterol and ~55% reduction in triglycerides within two weeks; reductions persisted for at least 60 days.
- Treatment: Single intravenous infusion of a CRISPR-Cas9 therapy targeting a liver gene that regulates cholesterol.
- Safety: No serious adverse events reported in the short-term follow-up; larger, longer trials required.
Study details
This first-in-human Phase 1 pilot trial enrolled 15 adults whose high cholesterol and triglycerides had not responded to standard medicines. The trial ran from June 2024 through August 2025 at six sites in Australia, New Zealand and the United Kingdom. Investigators administered a single intravenous infusion of a CRISPR-Cas9 gene-editing therapy designed to target a liver gene involved in cholesterol regulation.
What researchers did
Doctors measured baseline blood levels of LDL cholesterol and triglycerides, gave one infusion, then followed patients for safety and early signs of lasting benefit. The pilot results and summary were reported by the Cleveland Clinic newsroom.
Results in plain terms
After one infusion, average LDL — the “bad” cholesterol tied to heart attacks — fell by about 50% within two weeks. Triglycerides dropped roughly 55%. These lowered levels persisted for at least 60 days in this early report. Investigators emphasized that longer-term follow-up is under way to assess durability.
Safety and limits
So far, the therapy appears safe in the short term: the trial reported no serious adverse events tied to the gene edit during the limited follow-up. But the study was small and follow-up covered only weeks to months, so rare or delayed complications may not yet be visible. Larger, longer trials are needed to confirm safety and durability.
How the gene edit works
The treatment uses CRISPR-Cas9, which cuts DNA at a specific spot. Doctors deliver the CRISPR system to the liver to disable a gene that helps the body make or retain harmful cholesterol. By editing liver cells directly, the approach aims to lower LDL and triglycerides from within the body rather than by blocking pathways with pills or injections.
Expert perspective
Study leaders call the results the first clinical evidence that CRISPR gene-editing can safely and effectively lower dangerous lipids in people.
“Rather than a once-daily pill or monthly injection, this therapy would potentially offer a one-time infusion that is safe and durable for patients with high cholesterol,” said Dr. Luke Laffin, the study’s lead author.
Researchers urged caution: findings are promising but preliminary.
Why this matters now
High LDL and triglycerides are major drivers of heart disease, the leading U.S. killer. Many patients rely on daily statins or periodic injectables but still fail to reach safe levels or cannot tolerate treatments. A durable, one-time gene-editing infusion could transform prevention of heart attacks for people with persistent, high-risk lipid disorders.
Regulatory and ethical considerations
Because CRISPR permanently alters DNA in targeted cells, regulators will demand robust long-term safety data before approval. Key questions include effect duration, off-target edits, and possible late-emerging liver or immune complications. The therapy remains investigational and is available only in clinical trials at present; see the Cleveland Clinic newsroom summary.
Practical hurdles and costs
Even if larger trials confirm benefits, questions remain about pricing, payer coverage, and equitable access. One-time advanced therapies often carry high upfront costs that could limit access. If the infusion prevents years of medications and hospital visits, it could be cost-effective — but that depends on long-term data and pricing decisions.
What patients should know
Patients with stubborn high cholesterol should not expect immediate access. For now, continue standard care — lifestyle changes and guideline-directed medicines such as statins, ezetimibe, or PCSK9 inhibitors. Patients interested in trials should discuss options with their cardiologist and check reputable trial registries.
Study context and next steps
This small pilot was conducted outside the U.S.; researchers plan larger, multi-center trials with longer follow-up and more diverse participants. U.S. regulators will evaluate those data before any approval. The work was presented at the American Heart Association’s Scientific Sessions 2025 and summarized by the Cleveland Clinic newsroom.
Implications for the United States
Economic: If proven durable and safe, a one-time gene-editing therapy could reshape health spending decisions for insurers and Medicare.
Political: Policymakers may debate rules on gene therapies, pricing, and access.
Social: Ensuring equitable access and diverse trial enrollment will be crucial to avoid widening health disparities.
Sources and further reading
Cleveland Clinic newsroom: “First-in-human trial of CRISPR gene-editing therapy shown to safely lower cholesterol and triglycerides”
Presentation at the American Heart Association Scientific Sessions 2025 and article in the New England Journal of Medicine (pilot study details as reported by the Cleveland Clinic newsroom).
Reporting note: This article uses findings reported by the Cleveland Clinic summarizing the pilot study published in the New England Journal of Medicine and presented at the American Heart Association’s Scientific Sessions 2025. The CRISPR gene-editing cholesterol approach remains experimental and is not approved for general use.
